多西紫杉醇联合化疗治疗激素抵抗性前列腺癌的临床分析  

Clinical analysis of docetaxel combination chemotherapy in hormone resistant prostate cancer

作　　者：王威 

机构地区：[1]许昌市中心医院泌尿外科,河南许昌461000

出　　处：《医药论坛杂志》2016年第3期52-54,共3页Journal of Medical Forum

摘　　要：目的探讨多西紫杉醇为基础的联合化疗在激素难治性前列腺癌中的应用价值。方法将56例HRPC患者随机分成两组,分别给予多西紫杉醇加泼尼松治疗(泼尼松组)和多西紫杉醇加雌二醇氮芥(雌二醇氮芥组)治疗,分析比较疗效及不良反应。结果治疗后完全缓解3例(5.4%),部分缓解9例(16.1%),稳定33例(58.9%),进展11例(19.6%)。泼尼松组与雌二醇氮芥组在治疗有效率中无统计学意义(P<0.05);泼尼松组治疗后生活质量提高12例(40.0%),雌二醇氮芥组为7例(26.9%),两组差异有统计学意义(P<0.05);泼尼松组不良反应发生率明显低于雌二醇氮芥组,有统计学意义(P<0.05)。结论多西紫杉醇为基础的联合化疗对激素难治性前列腺癌有较好临床疗效,其中多西紫杉醇联合泼尼松治疗不良反应轻,更易耐受。Objective To evaluate the efficacy of docetaxel- based combination chemotherapy in hormone refractory prostate cancer. Methods Totally 56 cases of HRPC patients were randomly divided into two groups and were treated with docetaxel plus prednisone therapy and docetaxel plus nitrogen mustard of estradiol,the comparative efficacy and toxicity was analyzed. Results Totally 3 cases were complete remission after treatment（ 5. 4%）,partial remission in 9 cases（ 16. 1%）,stabilized in 33 cases（ 58. 9%）,and the progress of 11 cases（ 19. 6%）. There was no differences in treatment efficiency between prednisone group and estradiol and nitrogen mustard group（ P〈0. 05）; prednisone group improved quality of life after treatment,13 cases（ 40. 0%）,estradiol nitrogen mustard group,5 cases（ 26. 9%）,the difference was significant（ P〈0. 05）; The incidence of adverse reactions in prednisone group was significantly lower than that of the nitrogen mustard estradiol group（ P〈0. 05）. Conclusion Docetaxel- based combination chemotherapy for hormone refractory prostate cancer have good clinical efficacy,and docetaxel plus prednisone therapy has lighter reaction and better toleration to toxicity.

关 键 词：前列腺癌 多西紫杉醇 雌二醇氮芥 泼尼松 化学治疗 

分 类 号：R737.25[医药卫生—肿瘤]